Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 14, 2016 4:55 PM ET


Company Overview of REGiMMUNE Corporation

Company Overview

REGiMMUNE Corporation, a biotechnology company, engages in the discovery, development, and commercialization of immune-regulatory therapeutics to treat life-threatening diseases and debilitating disorders. Its products include RGI-2001 for graft versus host disease (GvHD) associated with hematopoietic stem cell transplantation (HSCT) as a proof of concept; and RGI-3010, a immunetolenance inducing liposome encapsulating proinsulin designed to increase the number of regulatory T cells and tolerize the immune system to proinsulin, thereby turning off the self directed immune attack. The company was founded in 2006 and is headquartered in Tokyo, Japan. It has an additional office in Mountain Vie...

1-7-8 Kaigan

Tokyo Industry Trade Center 607 (6th Floor)


Tokyo,  105-0022


Founded in 2006


81 3 6809 2199

Key Executives for REGiMMUNE Corporation

Co-Founder, Chief Executive Officer, President and Non-Executive Director
Chief Development Officer and Senior Director
Compensation as of Fiscal Year 2015.

REGiMMUNE Corporation Key Developments

REGiMMUNE Corporation Appoints Joseph Mccracken to its Board of Directors

REGiMMUNE Corporation announced that the Company has appointed Joseph McCracken to its Board of Directors. Dr. McCracken currently advises biopharmaceutical companies on the design and implementation of corporate strategy and business development initiatives, and serves on the Board of Alkahest Inc., Genkyotex S.A., Savara Pharmaceuticals and Nexvet Biopharma. Dr. McCracken was previously Vice President and Global Head of Business Development & Licensing for Roche Pharma, where he was responsible for Roche Pharma’s global in-licensing and out-licensing activities.

REGiMMUNE Corporation Presents at BIO-Europe 2014, Nov-04-2014 02:45 PM

REGiMMUNE Corporation Presents at BIO-Europe 2014, Nov-04-2014 02:45 PM. Venue: Portalhaus Messe Frankfurt, Strasse der Nationen, 60327 Frankfurt, Germany.

REGiMMUNE Corporation to Present Its Method for Long-Term Tolerance in Organ Transplantation at World Transplant Congress in San Francisco

REGiMMUNE Corporation announced that it will present results from its research on its novel approach to long-term tolerance in organ transplantation without continuous administration of immune suppressants at the World Transplant Congress (WTC) on Tuesday, July 29, 2014. Robust, lifelong, donor-specific tolerance can be reliably achieved by induction of mixed chimerism in various animal models of bone transplantation. To date, the clinical application of these protocols has been impeded by the potential toxicity of the required host conditioning regimens. The REGiMMUNE poster presents the potential of a novel approach using a ligand alpha-GalCer (aGC) for iNKT cells and suboptimal dosage of antibody that blocks CD40:CD40L signaling as a powerful method to generate mixed chimerism. Invariant natural killer T (iNKT) cells are one of the innate lymphocytes that regulate immunity, although it is still elusive how iNKT cells should be manipulated for transplant tolerance. It previously reported that the liposomal formulation of -galactosylceramide (Lipo-aGC) could enhance immune-regulative aspect of iNKT cells compared to the conventional aGC. Here describe a novel approach to induce mixed chimerism (MC) by activating iNKT cells with Lipo-aGC under CD40-CD40L blockade (MR1). 3Gy irradiated BALB/c mice were transplanted with B6 bone marrow cells (BMC s) with/without Lipo-aGC and/or several dosages of MR1. Only combination therapy of Lipo-aGC plus suboptimal-MR1 showed robust MC. Mice established MC completely accepted subsequent cardiac allografts in a donor-specific manner. High amounts of Th2-cytokines were detected right after iNKT-cell activation, while subsequent IFN- production by NK cells was effectively inhibited by MR1. Expansion of regulatory T cells (Tregs) was observed in MC mice and Treg-depletion on 1 day before transplantation resulted MC brake. Further, iNKT-cell knockout mice failed both MC establishment and Tregs expansion. These results collectively suggest that new protocol makes it possible to induce donor-specific tolerance by enhancement of the innate regulatory mechanism in place of the conventional immunosuppression.

Similar Private Companies By Industry

Company Name Region
Bio Matrix Research, Inc. Asia
Amgen Development KK Asia
Cardio Incorporated Asia
HuBit Genomix Inc. Asia
ASPION Corporation Asia

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact REGiMMUNE Corporation, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at